1. Mechanisms of Granulocytopoiesis Recovery Stimulation with Filgrastim in Breast Cancer Patients Receiving Chemotherapy.
- Author
-
Goldberg VE, Polyakova TY, Popova NO, Vysotskaya VV, Simolina EI, Dudnikova EA, Goncharova NM, Belevich YV, Tuzikova TP, Goldberg AV, Miroshnichenko LA, Udut EV, Simanina EV, Zyuz'kov GN, Zhdanov VV, and Dygai AM
- Subjects
- Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Female, Fluorouracil therapeutic use, Granulocyte Colony-Stimulating Factor metabolism, Humans, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Filgrastim therapeutic use, Granulocytes cytology, Granulocytes drug effects
- Abstract
We studied myelotoxicity of modern schemes of chemotherapy for breast cancer (docetaxel/doxorubicin and cyclophosphamide/doxorubicin/5-fluorouracil) towards granulocytopoiesis, the mechanisms determining the differences of hematological effects of these schemes, and the efficiency of correction of the observed changes with granulocyte CSF (filgrastim). Granulocytopoiesis stimulation with filgrastim during the treatment with docetaxel/doxorubicin combination was more pronounced than during cyclophosphamide/doxorubicin/5-fluorouracil therapy. The observed differences were found at all levels of granulocyte lineage organization (central and peripheral), which is related to different effects of the cytostatic substances used in the proposed protocols on the structures controlling hemopoiesis.
- Published
- 2018
- Full Text
- View/download PDF